+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Dementia - Pipeline Review, H2 2019

  • ID: 4861720
  • Drug Pipelines
  • November 2019
  • Region: Global
  • 371 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

FEATURED COMPANIES

  • Actinogen Medical Ltd
  • Annovis Bio Inc
  • Eli Lilly and Co
  • Ionis Pharmaceuticals Inc
  • Neurimmune Holding AG
  • Prevail Therapeutics Inc
  • MORE
Dementia - Pipeline Review, H2 2019

Summary

The Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Dementia - Pipeline Review, H2 2019, provides an overview of the Dementia (Central Nervous System) pipeline landscape.

Dementia is the loss of mental functions such as thinking, memory, and reasoning that is severe enough to interfere with a person's daily functioning. Symptoms include memory loss, hallucinations, agitation, personality changes and difficulty with coordination and motor functions. Risk factors include age, smoking, obesity, high blood pressure, inflammation and cardiovascular diseases.

Report Highlights

The Publisher's Pharmaceutical and Healthcare latest pipeline guide Dementia - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Dementia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Dementia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Dementia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 6, 21, 14, 50, 20 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 9 and 3 molecules, respectively.

Dementia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from The Publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Dementia (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Dementia (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Dementia (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Dementia (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Dementia (Central Nervous System)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Dementia (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Dementia (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Actinogen Medical Ltd
  • Annovis Bio Inc
  • Eli Lilly and Co
  • Ionis Pharmaceuticals Inc
  • Neurimmune Holding AG
  • Prevail Therapeutics Inc
  • MORE
Introduction
Dementia - Overview
Dementia - Therapeutics Development
Dementia - Therapeutics Assessment
Dementia - Companies Involved in Therapeutics Development
Dementia - Drug Profiles
Dementia - Dormant Projects
Dementia - Discontinued Products
Dementia - Product Development Milestones
Appendix

List of Tables
Number of Products under Development for Dementia, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Products under Development by Companies, H2 2019 (Contd..4), H2 2019
Products under Development by Companies, H2 2019 (Contd..5), H2 2019
Products under Development by Companies, H2 2019 (Contd..6), H2 2019
Products under Development by Universities/Institutes, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..2), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..2), H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Dementia - Pipeline by Acadia Pharmaceuticals Inc, H2 2019
Dementia - Pipeline by Actinogen Medical Ltd, H2 2019
Dementia - Pipeline by AcuraStem Inc, H2 2019
Dementia - Pipeline by Adamed Sp zoo, H2 2019
Dementia - Pipeline by ADEL Inc, H2 2019
Dementia - Pipeline by AgeneBio Inc, H2 2019
Dementia - Pipeline by Aibios Co Ltd, H2 2019
Dementia - Pipeline by Alector Inc, H2 2019
Dementia - Pipeline by Allergan Plc, H2 2019
Dementia - Pipeline by Alterity Therapeutics Ltd, H2 2019
Dementia - Pipeline by Anavex Life Sciences Corp, H2 2019
Dementia - Pipeline by Annovis Bio Inc, H2 2019
Dementia - Pipeline by Asceneuron SA, H2 2019
Dementia - Pipeline by Axon Neuroscience SE, H2 2019
Dementia - Pipeline by Axovant Gene Therapies Ltd, H2 2019
Dementia - Pipeline by Biogen Inc, H2 2019
Dementia - Pipeline by BioXcel Therapeutics Inc, H2 2019
Dementia - Pipeline by Boehringer Ingelheim International GmbH, H2 2019
Dementia - Pipeline by Bolder Biotechnology Inc, H2 2019
Dementia - Pipeline by Cennerv Pharma (S) Pte Ltd, H2 2019
Dementia - Pipeline by Cortice Biosciences Inc, H2 2019
Dementia - Pipeline by Daewoong Pharmaceutical Co Ltd, H2 2019
Dementia - Pipeline by Denali Therapeutics Inc, H2 2019
Dementia - Pipeline by EIP Pharma LLC, H2 2019
Dementia - Pipeline by Eisai Co Ltd, H2 2019
Dementia - Pipeline by Eli Lilly and Co, H2 2019
Dementia - Pipeline by Ensol Biosciences Inc, H2 2019
Dementia - Pipeline by Enterin Inc, H2 2019
Dementia - Pipeline by EVER Neuro Pharma GmbH, H2 2019
Dementia - Pipeline by Galimedix Therapeutics Ltd, H2 2019
Dementia - Pipeline by Gismo Therapeutics Inc, H2 2019
Dementia - Pipeline by Guangzhou Magpie Pharmaceutical Co Ltd, H2 2019
Dementia - Pipeline by GW Pharmaceuticals Plc, H2 2019
Dementia - Pipeline by HanAll Biopharma Co Ltd, H2 2019
Dementia - Pipeline by Hyundai Pharmaceutical Co Ltd, H2 2019
Dementia - Pipeline by Immungenetics AG, H2 2019
Dementia - Pipeline by ImStar Therapeutics Inc, H2 2019
Dementia - Pipeline by Inhibikase Therapeutics Inc, H2 2019
Dementia - Pipeline by IntraBio Ltd, H2 2019
Dementia - Pipeline by INVENT Pharmaceuticals Inc, H2 2019
Dementia - Pipeline by Ionis Pharmaceuticals Inc, H2 2019
Dementia - Pipeline by iQure Pharma Inc, H2 2019
Dementia - Pipeline by IRLAB Therapeutics AB, H2 2019
Dementia - Pipeline by Johnson & Johnson, H2 2019
Dementia - Pipeline by Kogenix Therapeutics Inc, H2 2019
Dementia - Pipeline by LA Cell Inc, H2 2019
Dementia - Pipeline by Lachesis Biosciences Ltd, H2 2019
Dementia - Pipeline by Luye Pharma Group Ltd, H2 2019
Dementia - Pipeline by MediPost Co Ltd, H2 2019
Dementia - Pipeline by MGC Pharmaceuticals Ltd, H2 2019
Dementia - Pipeline by Neuraltus Pharmaceuticals Inc, H2 2019
Dementia - Pipeline by Neurimmune Holding AG, H2 2019
Dementia - Pipeline by Neurodyn Cognition Inc, H2 2019
Dementia - Pipeline by NeuroScientific Biopharmaceuticals Ltd, H2 2019

List of Figures
Number of Products under Development for Dementia, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Number of Products by Top 10 Targets, H2 2019
Number of Products by Stage and Top 10 Targets, H2 2019
Number of Products by Top 10 Mechanism of Actions, H2 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Number of Products by Top 10 Routes of Administration, H2 2019
Number of Products by Stage and Top 10 Routes of Administration, H2 2019
Number of Products by Top 10 Molecule Types, H2 2019
Number of Products by Stage and Top 10 Molecule Types, H2 2019
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Acadia Pharmaceuticals Inc
  • Actinogen Medical Ltd
  • AcuraStem Inc
  • Adamed Sp zoo
  • ADEL Inc
  • AgeneBio Inc
  • Aibios Co Ltd
  • Alector Inc
  • Allergan Plc
  • Alterity Therapeutics Ltd
  • Anavex Life Sciences Corp
  • Annovis Bio Inc
  • Asceneuron SA
  • Axon Neuroscience SE
  • Axovant Gene Therapies Ltd
  • Biogen Inc
  • BioXcel Therapeutics Inc
  • Boehringer Ingelheim International GmbH
  • Bolder Biotechnology Inc
  • Cennerv Pharma (S) Pte Ltd
  • Cortice Biosciences Inc
  • Daewoong Pharmaceutical Co Ltd
  • Denali Therapeutics Inc
  • EIP Pharma LLC
  • Eisai Co Ltd
  • Eli Lilly and Co
  • Ensol Biosciences Inc
  • Enterin Inc
  • EVER Neuro Pharma GmbH
  • Galimedix Therapeutics Ltd
  • Gismo Therapeutics Inc
  • Guangzhou Magpie Pharmaceutical Co Ltd
  • GW Pharmaceuticals Plc
  • HanAll Biopharma Co Ltd
  • Hyundai Pharmaceutical Co Ltd
  • Immungenetics AG
  • ImStar Therapeutics Inc
  • Inhibikase Therapeutics Inc
  • IntraBio Ltd
  • INVENT Pharmaceuticals Inc
  • Ionis Pharmaceuticals Inc
  • iQure Pharma Inc
  • IRLAB Therapeutics AB
  • Johnson & Johnson
  • Kogenix Therapeutics Inc
  • LA Cell Inc
  • Lachesis Biosciences Ltd
  • Luye Pharma Group Ltd
  • MediPost Co Ltd
  • MGC Pharmaceuticals Ltd
  • Neuraltus Pharmaceuticals Inc
  • Neurimmune Holding AG
  • Neurodyn Cognition Inc
  • NeuroScientific Biopharmaceuticals Ltd
  • NLS Pharma Group
  • Novartis AG
  • Oryzon Genomics SA
  • Otsuka Holdings Co Ltd
  • P2D Inc
  • Pacific Northwest Biotechnology LLC
  • Park Active Molecules
  • Passage Bio Inc
  • Plico Biotech Inc
  • Prevail Therapeutics Inc
  • ProMIS Neurosciences Inc
  • Prothena Corp Plc
  • Psy Therapeutics Inc
  • Rodin Therapeutics Inc
  • SanBio Inc
  • Sinfonia Biotherapeutics Inc
  • Stemedica Cell Technologies Inc
  • Sun Pharma Advanced Research Company Ltd
  • SyneuRx International Corp
  • TauRx Therapeutics Ltd
  • Theranexus SAS
  • UniQure NV
  • Voyager Therapeutics Inc
  • WAVE Life Sciences Ltd
  • WhanIn Pharmaceutical Co Ltd
Note: Product cover images may vary from those shown
Adroll
adroll